VBIO Valion Bio, Inc. - Common stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 14, 2026VBIO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
VBIO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| Aug. 31, 2026 | 1-for-25 | Reverse |
| March 7, 2025 | 1-for-17 | Reverse |
| Aug. 23, 2023 | 1-for-100 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | VBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 2.5 | · | · | · | |
| Price / Tangible Book (MRQ) | 5.4 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | VBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 1.1 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2024 | $-0.32 | $-6.12 | 94.8% | |
| Sept. 30, 2023 | $-25.16 | $-121.38 | 79.3% | |
| June 30, 2023 | $-119.00 | $-138.72 | 14.2% | |
| Dec. 31, 2022 | $-289.00 | $-398.82 | 27.5% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| R&D Expense | $3M | · | $655.0K | |
| SG&A Expense | $4M | · | $1M | |
| Operating Expenses | $6M | · | $2M | |
| Operating Income | $-6M | · | $-2M | |
| Interest Income | $11.0K | · | $3.0K | |
| Other Non-op | $-633.0K | · | $3.0K | |
| Net Income | $-7M | · | $-2M | |
| EPS (Basic) | $-2.17 | · | $-2.19 | |
| Shares (Basic) | 3,379,997 | · | 881,294 | |
| EBITDA | $-6M | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $2M | · | · | |
| Inventory | $750.0K | · | · | |
| Prepaid Expense | $524.0K | · | · | |
| Current Assets | $3M | · | · | |
| PP&E (Net) | $12M | · | · | |
| PP&E (Gross) | $13M | · | · | |
| Accum. Depreciation | $377.0K | · | · | |
| Goodwill | $3M | · | · | |
| Intangibles | $2M | · | · | |
| Other Non-current Assets | $214.0K | · | · | |
| Total Assets | $32M | · | · | |
| Accounts Payable | $639.0K | · | · | |
| Current Liabilities | $3M | · | · | |
| Capital Leases | $9M | · | · | |
| Other Non-current Liabilities | $454.0K | · | · | |
| Total Liabilities | $21M | · | · | |
| Common Stock | $2.0K | · | · | |
| Paid-in Capital | $71M | · | · | |
| Retained Earnings | $-67M | · | · | |
| Stockholders' Equity | $4M | · | · | |
| Liabilities + Equity | $32M | · | · | |
| Shares Outstanding | 4,151,919 | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| Stock-based Comp | $133.0K | · | · | |
| Operating Cash Flow | $-5M | · | · | |
| CapEx | $57.0K | · | · | |
| Investing Cash Flow | $-57.0K | · | · | |
| Financing Cash Flow | $231.0K | · | · | |
| Net Change in Cash | $-5M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| ROA | -38.4% | · | · | |
| ROE | -179.1% | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| Current Ratio | 1.1 | · | · | |
| Quick Ratio | 0.7 | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| Book Value / Share | $1.02 | · | · | |
| Cash / Share | $0.51 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| Net Income TTM | $-19M | $-8M | $-6M | |
| Market Cap | $2M | · | · | |
| P/B | 0.5 | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| 3i Management LLC, 3i, LP, Maier J. Tarlow, Tumim Stone Capital, LLC ×5 filings | Sept. 3, 2026 | 9.90% | Amendment | · | SEC |
| 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, Maier J. Tarlow ×3 filings | Aug. 14, 2026 | 9.90% | Amendment | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 12 insiders · 9 officers · 6 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Dean Zikria | Interim CEO | Sept. 22, 2026 A | · | 0 | 0 | $0 |
| Michael K Handley | Chief Executive Officer | May 18, 2026 M | 11,030 | 0 | 0 | $0 |
| Jennifer Ernst | Chief Executive Officer | Dec. 18, 2025 M | 32,691 | 0 | 0 | $0 |
| Lisa G Wolf | COO & CFO | Sept. 18, 2026 M | 27 | 0 | 0 | $0 |
| Kimberly Ann Bambach | Interim CFO | March 12, 2024 A | 7,500 | 0 | 0 | $0 |
| Veronica Cai | Chief Financial Officer | April 1, 2022 A | · | 0 | 0 | $0 |
| Ryan Sabia | Chief Operating Officer | May 8, 2023 A | · | 0 | 0 | $0 |
| Melinda Lackey | General Counsel & SVP of Legal | May 1, 2026 A | · | 0 | 0 | $0 |
| Blake Gurfein | Chief Scientific Officer | Dec. 18, 2024 A | · | 0 | 0 | $0 |
| Sheryle Bolton | Director | April 15, 2026 P | 10,000 | 1 | 0 | $10,400 |
| Christina Rizopoulos Valauri | Director | April 1, 2026 P | 19,000 | 1 | 0 | $18,050 |
| Karen Drexler | Director | Aug. 9, 2024 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.